Medichem opens Malta HPAPI plant

By Gareth Macdonald

- Last updated on GMT

Medichem opens Malta HPAPI plant

Related tags Pharmacology

Medichem has opened an API plant in Malta touting the country’s “unique patent situation” as an attractive option for generic drugmakers.

The Spanish active pharmaceutical ingredient (API) firm’s new facility in Hal Far will make high potency drug actives for clinical assessment and commercial supply and is expected to be fully operational in the second half of the year.

Medichem CEO Ervin Veszprémi cited growing demand from generic drugmakers for HPAPIs adding that: “Our expansion to HPAI field will allow Medichem to offer a broader product portfolio to our customers​.”

The firm also highlighted Malta’s patent laws as an important part of its decision to set up the facility, explaining that its “legal and intellectual property (IP) framework allows Medichem to offer first-to-market opportunities to its customers worldwide​.”

Malta’s attraction as an API production hub is dependent on two factors: the small size of the market, which means that comparatively few drug patents have been registered in the country; and its broad interpretation of legislation covering research and development.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars